A share price of Macrogenics Inc [MGNX] is currently trading at $20.72, up 8.71%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MGNX shares have gain 23.26% over the last week, with a monthly amount glided 35.69%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 1, March 2024, MacroGenics to Participate in Upcoming Investor Conferences. In a post published today on Yahoo Finance, MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company’s management will participate in the following investor conferences in March 2024:.
From an analyst’s perspective:
Macrogenics Inc [NASDAQ: MGNX] stock has seen the most recent analyst activity on March 04, 2024, when BTIG Research reiterated its Buy rating and also boosted its price target to $24 from $12. Previously, H.C. Wainwright downgraded its rating to Neutral on February 14, 2024, and elevated its price target to $14. On December 20, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $13 on the stock. Guggenheim upgraded its rating to a Buy but stick to its price target of $12 on November 07, 2023. Guggenheim downgraded its rating to a Neutral. Cowen downgraded its rating to Market Perform for this stock on November 22, 2022. In a note dated November 14, 2022, BMO Capital Markets upgraded an Outperform rating on this stock and boosted its target price from $5.70 to $16.
Macrogenics Inc experienced fluctuations in its stock price throughout the past year between $4.29 and $19.39. Currently, Wall Street analysts expect the stock to reach $16.67 within the next 12 months. Macrogenics Inc [NASDAQ: MGNX] shares were valued at $20.72 at the most recent close of the market. An investor can expect a potential drop of -19.55% based on the average MGNX price forecast.
Analyzing the MGNX fundamentals
Trailing Twelve Months sales for Macrogenics Inc [NASDAQ:MGNX] were 121.13M which represents -75.09% decline. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -0.9%, Pretax Profit Margin comes in at 0.42%, and Net Profit Margin reading is 0.42%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.32 and Total Capital is -0.37. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.82 points at the first support level, and at 18.92 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.21, and for the 2nd resistance point, it is at 21.70.
Macrogenics Inc [MGNX] reported earnings per share of $0.28 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.1/share, meaning a difference of $0.38 and a surprise factor of 380.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were $0.92 per share as compared to estimates of -$0.52 per share, a difference of $1.44 representing a surprise of 276.90%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Macrogenics Inc [NASDAQ:MGNX] is 5.68. As well, the Quick Ratio is 5.66, while the Cash Ratio is 1.75. Considering the valuation of this stock, the price to sales ratio is 10.61, the price to book ratio is 6.63 and price to earnings (TTM) ratio is 25.98.
Transactions by insiders
Recent insider trading involved Peters Jeffrey Stuart, Senior VP and General Counsel, that happened on Feb 26 when 16124.0 shares were sold. Sr VP, Research & CSO, Bonvini Ezio completed a deal on Feb 07 to sell 3334.0 shares. Meanwhile, Senior VP and General Counsel Peters Jeffrey Stuart sold 76251.0 shares on Feb 05.
